Cellay Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 13

Employees

  • Latest Deal Type
  • Debt - PPP

  • Investors
  • 1

Cellay General Information

Description

Developer of chromosomes technology solution platform intended to facilitate the hybridization of fish. The company's platform involves manufacturing and selling oligo fluorescence in situ hybridization as analyte-specific reagents for chromosome enumeration, enabling users to increase throughput and reduce costs while using your current workflow and imaging equipment.

Contact Information

Website
www.cellayinc.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 100 Inman Street
  • Suite 200
  • Cambridge, MA 02139
  • United States
+1 (617)
Primary Industry
Biotechnology
Other Industries
Other Commercial Products
Vertical(s)
Manufacturing
Corporate Office
  • 100 Inman Street
  • Suite 200
  • Cambridge, MA 02139
  • United States
+1 (617)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cellay Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Debt - PPP 15-Apr-2020 Completed Generating Revenue
3. Secondary Transaction - Private Completed Generating Revenue
2. Seed Round 06-Jul-2009 $1M $1M Completed Startup
1. Grant 01-Jan-2009 $30K Completed Startup
To view Cellay’s complete valuation and funding history, request access »

Cellay Patents

  • 24

    Total Documents Applications and Grants

  • Total Patents Families

  • 7

    Granted

  • Pending

  • Expiring in next 12 mo

Cellay Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3066214-B1 Methods and kits for detecting a prostate carcinoma and predicting disease outcomes for prostate cancers Inactive 07-Nov-2013
US-20150126395-A1 Methods and kits for detecting a prostate carcinoma and predicting disease outcomes for prostate cancers Inactive 07-Nov-2013
AU-2014346735-A1 Methods and kits for detecting a prostate carcinoma and predicting disease outcomes for prostate cancers Inactive 07-Nov-2013
CA-2929932-A1 Methods and kits for detecting a prostate carcinoma and predicting disease outcomes for prostate cancers Inactive 07-Nov-2013
EP-3066214-A1 Methods and kits for detecting a prostate carcinoma and predicting disease outcomes for prostate cancers Active 07-Nov-2013 C12Q1/6886
To view Cellay’s complete patent history, request access »

Cellay Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cellay Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Science Foundation Government
To view Cellay’s complete investors history, request access »

Ready to get started?

Request a free trial

Cellay FAQs

  • When was Cellay founded?

    Cellay was founded in 2009.

  • Where is Cellay headquartered?

    Cellay is headquartered in Cambridge, MA.

  • What is the size of Cellay?

    Cellay has 13 total employees.

  • What industry is Cellay in?

    Cellay’s primary industry is Biotechnology.

  • Is Cellay a private or public company?

    Cellay is a Private company.

  • What is Cellay’s current revenue?

    The current revenue for Cellay is .

  • How much funding has Cellay raised over time?

    Cellay has raised $1M.

  • Who are Cellay’s investors?

    National Science Foundation has invested in Cellay.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »